Scholarlink

Background <p>Snakebites are problematic in many developing regions, including India, where over half of global snakebite deaths occur. Antivenoms are currently the only licensed treatment for snakebites. However, their use causes several challenges, most notably geographical limitations in efficacy and adverse side effects. Therefore, therapeutic alternatives are urgently needed. Recently, several studies have evaluated small molecule inhibitors (SMIs) and highlighted their promise as safe and effective alternatives to antivenoms. We investigate their potential use against Indian snakes, particularly Russell’s viper (<i>Daboia russelii</i>), responsible for over half of India’s snakebite cases.</p> Methods <p>Here, we explored the effectiveness of two phase-2-approved SMIs in countering the diverse and variable toxicities of <i>D. russelii</i> from across India.</p> Results <p>The phospholipase inhibitor varespladib and the metalloproteinase inhibitor marimastat, individually or in combination, effectively counter the toxicities of <i>D. russelii</i> venoms in vitro. Specific drug efficacy varies across geographic regions. These SMIs and their combination prevent lethality caused by the pan-Indian <i>D. russelii</i>, even in rescue experiments where treatment is delayed, in mice.</p> Conclusions <p>Our findings support the potential use of SMIs as effective, affordable, and accessible future therapies for treating bites from the world’s most medically important snake species.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Preclinical evaluation of small molecule inhibitors as early intervention therapeutics against Russell’s viper envenoming in India

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月10日

查看全文
  • Gotravalli V. Rudresha,
  • Suyog Khochare,
  • Nicholas R. Casewell,
  • Kartik Sunagar

摘要

Background

Snakebites are problematic in many developing regions, including India, where over half of global snakebite deaths occur. Antivenoms are currently the only licensed treatment for snakebites. However, their use causes several challenges, most notably geographical limitations in efficacy and adverse side effects. Therefore, therapeutic alternatives are urgently needed. Recently, several studies have evaluated small molecule inhibitors (SMIs) and highlighted their promise as safe and effective alternatives to antivenoms. We investigate their potential use against Indian snakes, particularly Russell’s viper (Daboia russelii), responsible for over half of India’s snakebite cases.

Methods

Here, we explored the effectiveness of two phase-2-approved SMIs in countering the diverse and variable toxicities of D. russelii from across India.

Results

The phospholipase inhibitor varespladib and the metalloproteinase inhibitor marimastat, individually or in combination, effectively counter the toxicities of D. russelii venoms in vitro. Specific drug efficacy varies across geographic regions. These SMIs and their combination prevent lethality caused by the pan-Indian D. russelii, even in rescue experiments where treatment is delayed, in mice.

Conclusions

Our findings support the potential use of SMIs as effective, affordable, and accessible future therapies for treating bites from the world’s most medically important snake species.